Humacyte's CTEV For Coronary Artery Bypass Grafting Accepted For Investigational New Drug Status For First-In-Human Trial By FDA
Share
Why It Matters
Humacyte got permission from the FDA to start testing a new artificial blood vessel in real people for heart surgery. This is an early step that shows the FDA thinks the idea is safe enough to try, which could be exciting if tests go well.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.